The majority (85–95%) of HHT patients have mutations either in the endoglin (ENG) gene (HHT1) or in the activin receptor-like kinase-1 (ACVRL1) gene (HHT2) [6–8]. The gene discussed is ACVRL1; the disease is hereditary hemorrhagic telangiectasia.